PRESS RELEASE | Basel, Switzerland, July 22, 2022

Versameb to present at the BIO Asia-Taiwan Conference

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its Chief Executive Officer, Klaas Zuideveld will be presenting  on the Company’s mRNA engineering technology platform VERSagile and lead therapeutic candidate VMB-100 at the BIO Asia-Taiwan Conference, taking place on 27-31 July 2022 in Taiwan.

The theme of the Conference is “Connecting the Asia Value Chain” and reflects the insights of the healthcare industry in the new era for innovation, supply, and investment, primarily focusing on Precision Medicine, Advanced Therapies, Digital Health, Investment and Collaboration, and Regional Partnerships with industry executives and investors from North America, Europe, and Asia to explore opportunities within Asia’s emerging biotech sector.

Versameb has developed a groundbreaking, proprietary technology platform which optimizes the application of functional RNA in different disease contexts. Its lead therapeutic candidate VMB-100 has demonstrated first-in-class potential for treatment of Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter.

BIO Asia-Taiwan Conference
Date: 27-31 July 2022, Taiwan
Presentation by: Klaas Zuideveld
Session: “New Modalities to Cure”
Date & Time: 27 July 2022, 16.00-16.15 Taipei time (10.00-10.15 CEST)

Klaas Zuideveld, Chief Executive Officer, said: “We are delighted to be presenting at the BIO Asia Taiwan Conference on our proprietary platform VERSagile amongst key industry executives and investors from North America, Europe and Asia, to demonstrate our commitment and focus as we continue to advance our pioneering next generation of RNA therapeutics to address the unmet medical needs of patients.”

If you would like to meet with the Versameb team at the above event, please contact us using the details provided below. For more information, please visit us at

Contact for media enquiries:

Dr Klaas Zuideveld, CEO

Optimum Strategic Communications
Mary Clark, Charlotte Hepburn-Scott, Zoe Bolt
Tel: +44 (0)20 3882 9621